A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for Breast Neoplasms
46 locations incl. Chandler
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06312176·Phase 3·Recruiting